JP2025517476A5 - - Google Patents

Info

Publication number
JP2025517476A5
JP2025517476A5 JP2024569253A JP2024569253A JP2025517476A5 JP 2025517476 A5 JP2025517476 A5 JP 2025517476A5 JP 2024569253 A JP2024569253 A JP 2024569253A JP 2024569253 A JP2024569253 A JP 2024569253A JP 2025517476 A5 JP2025517476 A5 JP 2025517476A5
Authority
JP
Japan
Prior art keywords
antibody
nectin
immunoconjugate
antibody fragment
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024569253A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025517476A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2023/063912 external-priority patent/WO2023227660A1/en
Publication of JP2025517476A publication Critical patent/JP2025517476A/ja
Publication of JP2025517476A5 publication Critical patent/JP2025517476A5/ja
Pending legal-status Critical Current

Links

JP2024569253A 2022-05-25 2023-05-24 ネクチン-4結合剤 Pending JP2025517476A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263345453P 2022-05-25 2022-05-25
US63/345,453 2022-05-25
PCT/EP2023/063912 WO2023227660A1 (en) 2022-05-25 2023-05-24 Nectin-4 binding agents

Publications (2)

Publication Number Publication Date
JP2025517476A JP2025517476A (ja) 2025-06-05
JP2025517476A5 true JP2025517476A5 (cg-RX-API-DMAC7.html) 2026-04-27

Family

ID=86710807

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024569253A Pending JP2025517476A (ja) 2022-05-25 2023-05-24 ネクチン-4結合剤

Country Status (11)

Country Link
US (1) US20250297004A1 (cg-RX-API-DMAC7.html)
EP (1) EP4532020A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025517476A (cg-RX-API-DMAC7.html)
KR (1) KR20250017209A (cg-RX-API-DMAC7.html)
CN (1) CN119233994A (cg-RX-API-DMAC7.html)
AU (1) AU2023276860A1 (cg-RX-API-DMAC7.html)
CA (1) CA3245954A1 (cg-RX-API-DMAC7.html)
IL (1) IL316140A (cg-RX-API-DMAC7.html)
MX (1) MX2024014288A (cg-RX-API-DMAC7.html)
TW (1) TW202411251A (cg-RX-API-DMAC7.html)
WO (1) WO2023227660A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
CN114845740B (zh) 2020-01-31 2026-06-02 先天制药公司 癌症的治疗
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
EP4719481A1 (en) * 2023-06-01 2026-04-08 BicycleTx Limited Bicyclic peptide ligands specific for nectin-4 and uses thereof
US20250213712A1 (en) * 2023-12-27 2025-07-03 Intocell, Inc. Antibody drug conjugates comprising camptothecin derivatives and uses thereof
WO2025148933A1 (zh) * 2024-01-08 2025-07-17 上海橙帆医药有限公司 抗体及其药物偶联物和用途
CN120383674A (zh) * 2024-01-26 2025-07-29 鲁南新时代生物技术有限公司 一种Nectin-4抗体及其应用
KR20250177512A (ko) * 2024-06-14 2025-12-24 삼성바이오에피스 주식회사 신규한 항-넥틴-4 항체 및 이의 용도
WO2025261506A1 (zh) * 2024-06-21 2025-12-26 信达生物制药(苏州)有限公司 抗Nectin-4抗体以及其用途

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
WO1999061061A1 (fr) 1998-05-22 1999-12-02 Daiichi Pharmaceutical Co., Ltd. Composites medicamenteux
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
CA2487932A1 (en) 2002-05-30 2003-12-11 Macrogenics, Inc. Cd16a binding proteins and use for the treatment of immune disorders
US7375234B2 (en) 2002-05-30 2008-05-20 The Scripps Research Institute Copper-catalysed ligation of azides and acetylenes
AU2003293666A1 (en) 2002-11-11 2004-06-03 Basf Aktiengesellschaft Method for the production of 2-keto-l-gulonic acid-c4-c10 alkyl esters
WO2004043493A1 (en) 2002-11-14 2004-05-27 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
CA2556752C (en) 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
ES2398975T3 (es) 2004-03-01 2013-03-25 Spirogen Sàrl Derivados de 11-hidroxi-5H-pirrolo[2,1-c][1,4]benzodiazepin-5-ona como intermedios clave para la preparación de pirrolobenzodiazepinas sustituidas en C2
US7807619B2 (en) 2004-11-01 2010-10-05 The Regents Of The University Of California Compositions and methods for modification of biomolecules
WO2007008848A2 (en) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
ES2708763T3 (es) 2005-07-07 2019-04-11 Seattle Genetics Inc Compuestos de monometilvalina que tienen modificaciones de la cadena lateral de fenilalanina en el extremo C
EP2907525B1 (en) 2007-11-21 2018-05-16 University Of Georgia Research Foundation, Inc. Dibenzocyclooctene-compounds for bioorthogonal reactions
FR2949469A1 (fr) 2009-08-25 2011-03-04 Sanofi Aventis Derives anticancereux, leur preparation et leur application en therapeutique
CN102711810B (zh) 2009-11-30 2015-04-22 詹森生物科技公司 效应子功能已消除的抗体Fc区突变体
WO2011121453A2 (en) 2010-03-30 2011-10-06 Clavis Pharma Asa Methods and compositions for treating or ameliorating cancer using gemcitabine-5'-elaidate
MX368648B (es) 2010-04-15 2019-10-09 Seattle Genetics Inc Pirrolobenzodiazepinas usadas para tratar enfermedades proliferativas.
ES2874306T3 (es) 2010-09-29 2021-11-04 Agensys Inc Conjugados de anticuerpos y fármacos (CAF) que se unen a las proteínas 191P4D12
CA2813411C (en) 2010-11-05 2016-08-02 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
SI2675480T1 (sl) 2011-02-15 2019-05-31 Immunogen, Inc. Metode priprave konjugatov
CA2858806A1 (en) 2011-12-23 2013-06-27 Innate Pharma Enzymatic conjugation of polypeptides
WO2013177481A1 (en) 2012-05-25 2013-11-28 Immunogen, Inc. Benzodiazepines and conjugates thereof
EP2916872B1 (en) 2012-11-09 2019-02-27 Innate Pharma Recognition tags for tgase-mediated conjugation
WO2014202773A1 (en) 2013-06-20 2014-12-24 Innate Pharma Enzymatic conjugation of polypeptides
PT3057585T (pt) 2013-10-15 2020-10-21 Seagen Inc Fármaco-ligadores peguilados para farmacocinética melhorada de conjugados de fármaco-ligando
EP3733209A1 (en) 2014-10-03 2020-11-04 Synaffix B.V. Sulfamide linker, conjugates thereof, and methods of preparation
ES2885854T3 (es) 2014-10-14 2021-12-15 Polytherics Ltd Proceso para la conjugación de un péptido o proteína con un reactivo que comprende un grupo saliente que incluye una porción de PEG
US11274160B2 (en) 2017-03-02 2022-03-15 INSERM (Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to Nectin-4 and uses thereof
EP3700577A1 (en) 2017-10-23 2020-09-02 Mablink Bioscience Ligand-drug-conjugate comprising a single molecular weight polysarcosine
CN113613679A (zh) 2019-03-19 2021-11-05 保罗·谢勒学院 基于甘氨酸的接头的转谷氨酰胺酶缀合方法
CN114845740B (zh) * 2020-01-31 2026-06-02 先天制药公司 癌症的治疗
KR20230060509A (ko) * 2020-09-04 2023-05-04 노바록 바이오테라퓨틱스 리미티드 넥틴-4 항체 및 이의 용도

Similar Documents

Publication Publication Date Title
KR102923527B1 (ko) 생체활성 분자 접합체, 이의 제조 방법 및 용도
US20240173427A1 (en) Glypican 3 antibodies and conjugates thereof
ES2804614T3 (es) Conjugados de polipéptidos manipulados usando transglutaminasa
AU2020338481B2 (en) Targeted dendrimer conjugates
JP2024501121A5 (cg-RX-API-DMAC7.html)
JP2016521256A (ja) 生物活性分子、そのコンジュゲート、及び治療用途
CN106795203A (zh) 用于抗体药物缀合物的稳定性调节接头
AU2015277100A1 (en) HER2 antibody-drug conjugates
CN106661123A (zh) 抗‑cd22抗体‑药物缀合物及其使用方法
BR112021010364A2 (pt) Composições farmacêuticas que compreendem conjugados de anticorpo-fármaco anti-191p4d12 e métodos de uso das mesmas
KR20250137203A (ko) 항체 약물 접합체
WO2017196764A1 (en) Antibody-drug conjugate of an anti-glypican-3 antibody and a tubulysin analog, preparation and uses
JP2025535447A (ja) 抗体-薬物コンジュゲート、その調製方法および使用
KR20250084935A (ko) 링커-페이로드 화합물, 접합체 및 이의 응용 분야
US20240269313A1 (en) Conjugates comprising a phosphorus(v) moiety and a drug
US20250127916A1 (en) Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload
CA3303751A1 (en) Cysteine-engineered antibody and immunoconjugate
TW202610635A (zh) 多特異性多藥物之抗體藥物結合物
WO2026011073A1 (en) Antibody drug conjugates